GNCC Capital (GNCP) Stock Jumps 50% Amid Updates News

GNCC Capital, Inc. (GNCP) confirms that it is currently reviewing its third-quarter report for possible reinstatement. The Board of Directors is in a good relationship with OTC Markets Compliance. GNCP stock overflows by 50% today to the cost of $0.0003. The Board of Directors of Proteus Pharmaceuticals believes that OTC Markets Compliance will not ask for any other amendments to the Third Quarter Reports. As a result, the company expects to be reinstated to the previous status without further delays.
The company knows that many of the shareholders don’t like the decision about the reinstatement. On contrary, the company asks them to be patient and wait for further updates.  There is a reminder for the investors that all of the filings are up to date and that the last filing was an amended filing for the third quarter ended September 30, 2021. As a result, the Annual Report and Letter for the year will be submitted by December 30, 2021, and will be filed on the OTC markets once again. GNCC Capital, Inc. is a Nevada corporation that through its subsidiary, BioCanns Pharma, SA, produces and sells pharmaceutical-grade oils.

Anthony Gonzales

Biotech, Tech, and Crypto reporterAnthony Gonzales brings 3 years of experience in helping grassroots, mid-sized organizations and large institutions strengthen their management and resource generating capacities and effectively plan for the future. He is also a mentor and professional advisor to artists working in all disciplines. He is the gold medalist from St. Marco University of Science and Technology in the Bachelors of Financial Management as well.